Alexion Pharmaceuticals (ALXN) was Reiterated by Barclays to “Equal Weight” while Lowering the Price Target of the company shares to $ 150 from a previous price target of $165 . Barclays advised their investors in a research report released on Jul 29, 2016.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.Shares were Reiterated by SunTrust on Jul 13, 2016 to “Buy” and Lowered the Price Target to $ 197 from a previous price target of $220 .
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Alexion Pharmaceuticals opened for trading at $134 and hit $135 on the upside on Thursday, eventually ending the session at $130.4, with a gain of 0.48% or 0.62 points. The heightened volatility saw the trading volume jump to 28,99,103 shares. Company has a market cap of $29,212 M.
In a different news, on Jun 14, 2016, John B Moriarty (EVP & General Counsel) sold 918 shares at $135.72 per share price. According to the SEC, on May 18, 2016, Martin Mackay (EVP & Global Head of R&D) sold 4,097 shares at $139.81 per share price. On May 13, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 53 shares at $138.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.